Your browser doesn't support javascript.
loading
Sotalol.
Kpaeyeh, John Alvin; Wharton, John Marcus.
Affiliation
  • Kpaeyeh JA; Division of Cardiology, Department of Medicine, Tourville Arrhythmia Center, Medical University of South Carolina, 114 Doughty Street, MSC 592, Charleston, SC 29425-5920, USA.
  • Wharton JM; Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, Tourville Arrhythmia Center, Medical University of South Carolina, 114 Doughty Street, BM 216, MSC 592, Charleston, SC 29425-5920, USA. Electronic address: whartonj@musc.edu.
Card Electrophysiol Clin ; 8(2): 437-52, 2016 Jun.
Article in En | MEDLINE | ID: mdl-27261833
ABSTRACT
Sotalol is effective for treating atrial fibrillation (AF), ventricular tachycardia, premature ventricular contractions, and supraventricular tachycardia. Racemic (DL) sotalol inhibits the rapid component of the delayed rectifier potassium current. There is a near linear relationship between sotalol dosage and QT interval prolongation. However, in dose ranging trials in patients with AF, low-dose sotalol was not more effective than placebo. Orally administered sotalol has a bioavailability of nearly 100%. The only significant drug interactions are the need to avoid or limit use of concomitant drugs that cause QT prolongation, bradycardia, and/or hypotension.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Sotalol / Anti-Arrhythmia Agents Type of study: Clinical_trials Limits: Humans Language: En Year: 2016 Type: Article

Full text: 1 Database: MEDLINE Main subject: Sotalol / Anti-Arrhythmia Agents Type of study: Clinical_trials Limits: Humans Language: En Year: 2016 Type: Article